Preparation and preclinical evaluation of Ga-labeled alendronate analogs for diagnosis of bone metastases.

Dalton Trans

Key Laboratory for Experimental Teratology of the Ministry of Education and Center for Experimental Nuclear Medicine, School of Basic Medical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, 250012, China.

Published: January 2025

Bone is one of the most common target organs for distant metastases of solid tumors, which imposes a heavy burden on society. Early diagnosis of bone metastases is of great significance and positron emission tomography (PET) imaging plays an important role in the diagnosis of bone metastases. PET tracers applied for diagnosing bone metastases are constantly being updated, but they all have certain limitations like a relatively low bone/kidney ratio or no capacity to label therapeutic radionuclides. Alendronate, a representative bisphosphonate (BP), has been usually considered the standard clinical treatment for bone related diseases. In this study, alendronate was strategically modified with different linkers in an attempt to improve target/non-target ratios and 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) was used as the chelator. Finally, three Ga-labeled tracers were successfully developed. The results showed that [Ga]Ga-AABP1/2/3 all exhibited high radiochemical purity, biosafety, and excellent stability. In the biodistribution study of normal BALB/c mice, [Ga]Ga-AABP3, when modified with phenylalanine and β-alanine as the linker, showed the highest bone/non-bone ratio at 1.5 h. In micro-PET/CT imaging of normal BALB/c mice, [Ga]Ga-AABP3 showed the highest SUV value at the bones (2.24 ± 0.16 at 1.5 h). In micro-PET/CT imaging of the mouse model of bone metastases, compared with [Ga]Ga-AABP1 and [Ga]Ga-AABP2, the SUV in the foci after injection of [Ga]Ga-AABP3 was the highest (2.64 ± 0.08 at 0.5 h and 2.67 ± 0.10 at 1.5 h), significantly higher than that of the contralateral normal bone. Besides, [Ga]Ga-AABP3 showed the highest tumor/non-tumor ratio at 1.5 h. The results suggest that [Ga]Ga-AABP3 has the potential for diagnosis of bone metastases. Furthermore, AABP3 with the chelator DOTA could also be labeled with Lu or Ac, providing possibility for further application in radioligand therapy.

Download full-text PDF

Source
http://dx.doi.org/10.1039/d4dt03159hDOI Listing

Publication Analysis

Top Keywords

bone metastases
24
diagnosis bone
16
[ga]ga-aabp3 highest
12
bone
9
normal balb/c
8
balb/c mice
8
mice [ga]ga-aabp3
8
micro-pet/ct imaging
8
metastases
7
[ga]ga-aabp3
5

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!